Clene Inc. 84C.F Stock
Clene Inc. Price Chart
Clene Inc. 84C.F Financial and Trading Overview
Clene Inc. stock price | 0.34 EUR |
Previous Close | 0.96 EUR |
Open | 0.96 EUR |
Bid | 0.71 EUR x N/A |
Ask | 0.77 EUR x N/A |
Day's Range | 0.96 - 0.96 EUR |
52 Week Range | 0.8 - 4.72 EUR |
Volume | 1 EUR |
Avg. Volume | 0 EUR |
Market Cap | 76.62M EUR |
Beta (5Y Monthly) | 0.360633 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.44 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 22.75 EUR |
84C.F Valuation Measures
Enterprise Value | 89.57M EUR |
Trailing P/E | N/A |
Forward P/E | -1.2307693 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 139.31485 |
Price/Book (mrq) | N/A |
Enterprise Value/Revenue | 162.846 |
Enterprise Value/EBITDA | -2.009 |
Trading Information
Clene Inc. Stock Price History
Beta (5Y Monthly) | 0.360633 |
52-Week Change | -74.86% |
S&P500 52-Week Change | 20.43% |
52 Week High | 4.72 EUR |
52 Week Low | 0.8 EUR |
50-Day Moving Average | 0.91 EUR |
200-Day Moving Average | 1.51 EUR |
84C.F Share Statistics
Avg. Volume (3 month) | 0 EUR |
Avg. Daily Volume (10-Days) | 0 EUR |
Shares Outstanding | 78.39M |
Float | 29.98M |
Short Ratio | N/A |
% Held by Insiders | 64.19% |
% Held by Institutions | 4.13% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -8328.18% |
Gross Margin | 94.36% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -61.40% |
Return on Equity (ttm) | -14530.25% |
Income Statement
Revenue (ttm) | 550K EUR |
Revenue Per Share (ttm) | 0.008 EUR |
Quarterly Revenue Growth (yoy) | 256.70% |
Gross Profit (ttm) | 447K EUR |
EBITDA | -44579000 EUR |
Net Income Avi to Common (ttm) | -28334000 EUR |
Diluted EPS (ttm) | -0.37 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 18.44M EUR |
Total Cash Per Share (mrq) | 0.24 EUR |
Total Debt (mrq) | 32.36M EUR |
Total Debt/Equity (mrq) | N/A |
Current Ratio (mrq) | 1.471 |
Book Value Per Share (mrq) | -0.021 |
Cash Flow Statement
Operating Cash Flow (ttm) | -35145000 EUR |
Levered Free Cash Flow (ttm) | -23500624 EUR |
Profile of Clene Inc.
Country | Germany |
State | UT |
City | Salt Lake City |
Address | 6550 South Millrock Drive |
ZIP | 84121 |
Phone | 801 676 9695 |
Website | https://clene.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 75 |
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.
Q&A For Clene Inc. Stock
What is a current 84C.F stock price?
Clene Inc. 84C.F stock price today per share is 0.34 EUR.
How to purchase Clene Inc. stock?
You can buy 84C.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Clene Inc.?
The stock symbol or ticker of Clene Inc. is 84C.F.
Which industry does the Clene Inc. company belong to?
The Clene Inc. industry is Biotechnology.
How many shares does Clene Inc. have in circulation?
The max supply of Clene Inc. shares is 128.43M.
What is Clene Inc. Price to Earnings Ratio (PE Ratio)?
Clene Inc. PE Ratio is now.
What was Clene Inc. earnings per share over the trailing 12 months (TTM)?
Clene Inc. EPS is -0.44 EUR over the trailing 12 months.
Which sector does the Clene Inc. company belong to?
The Clene Inc. sector is Healthcare.